1,220 Amgen Inc. $AMGN Shares Acquired by Penobscot Investment Management Company Inc.

Penobscot Investment Management Company Inc. raised its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 7.4% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 17,723 shares of the medical research company’s stock after buying an additional 1,220 shares during the period. Penobscot Investment Management Company Inc.’s holdings in Amgen were worth $7,470,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of the business. Rational Advisors Inc. raised its holdings in shares of Amgen by 13.7% in the second quarter. Rational Advisors Inc. now owns 199 shares of the medical research company’s stock worth $72,000 after buying an additional 24 shares during the period. Beacon Financial Advisory LLC lifted its stake in shares of Amgen by 2.0% during the 2nd quarter. Beacon Financial Advisory LLC now owns 1,274 shares of the medical research company’s stock worth $461,000 after acquiring an additional 25 shares during the last quarter. James T. Borello RIA boosted its holdings in Amgen by 13.6% during the 3rd quarter. James T. Borello RIA now owns 209 shares of the medical research company’s stock valued at $88,000 after acquiring an additional 25 shares during the period. Sweeney & Michel LLC boosted its holdings in Amgen by 0.5% during the 3rd quarter. Sweeney & Michel LLC now owns 5,129 shares of the medical research company’s stock valued at $2,162,000 after acquiring an additional 25 shares during the period. Finally, Legacy Financial Advisors Inc. boosted its holdings in Amgen by 0.8% during the 2nd quarter. Legacy Financial Advisors Inc. now owns 3,407 shares of the medical research company’s stock valued at $1,234,000 after acquiring an additional 26 shares during the period. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Amgen Stock Up 0.7%

Shares of NASDAQ:AMGN opened at $447.95 on Wednesday. The firm’s 50 day simple moving average is $418.42 and its 200-day simple moving average is $372.80. Amgen Inc. has a one year low of $288.00 and a one year high of $450.98.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Tuesday, August 4th. The medical research company reported $6.29 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.62 by $0.67. The firm had revenue of $10.05 billion during the quarter, compared to analysts’ expectations of $9.43 billion. The firm’s revenue for the quarter was up 9.5% on a year-over-year basis. During the same quarter in the previous year, the firm posted $6.02 EPS. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. As a group, equities analysts expect that Amgen Inc. will post 22.96 earnings per share for the current year.

Amgen Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, December 11th. Shareholders of record on Friday, November 20th will be given a dividend of $2.52 per share. The ex-dividend date of this dividend is Friday, November 20th. This represents a $10.08 dividend on an annualized basis and a yield of 2.3%.

Insiders Place Their Bets

In other news, SVP Rachna Khosla sold 1,252 shares of the firm’s stock in a transaction on Thursday, August 13th. The stock was sold at an average price of $416.43, for a total transaction of $521,370.36. Following the transaction, the senior vice president owned 6,404 shares in the company, valued at approximately $2,666,817.72. This trade represents a 16.35% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, SVP Nancy A. Grygiel sold 2,970 shares of Amgen stock in a transaction dated Thursday, August 6th. The shares were sold at an average price of $402.16, for a total value of $1,194,415.20. Following the completion of the sale, the senior vice president owned 7,340 shares of the company’s stock, valued at $2,951,854.40. The trade was a 28.81% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 6,222 shares of company stock valued at $2,540,926. 0.85% of the stock is currently owned by corporate insiders.

Trending Headlines about Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen reported positive Phase 3 results for dazodalibep in Sjögren’s disease, showing statistically significant and clinically meaningful improvements in systemic disease activity and patient-reported dryness. The company will also present long-term data for UPLIZNA and real-world evidence for KRYSTEXXA and TAVNEOS, strengthening its rare-disease and autoimmune pipeline. Amgen ACR Convergence 2026 data
• Positive Sentiment: New Phase 3 data for Amgen’s Imdelltra combined with AstraZeneca’s Imfinzi showed a 58% reduction in the risk of death in extensive-stage small-cell lung cancer, with median survival reaching 21.1 months. The results could improve the commercial outlook for Imdelltra, although execution and competition remain important considerations. Imdelltra and Imfinzi lung cancer results
• Positive Sentiment: Jefferies raised its Amgen price target to $428 from $410, while Barclays previously increased its target to $400 from $380. The revisions reflect improving sentiment around Amgen’s pipeline, though both targets remain below the current trading level. Jefferies raises Amgen price target
• Neutral Sentiment: Amgen appointed former Kimberly-Clark CEO David W. Gibbs to its board. The addition brings experienced leadership but is unlikely to materially change near-term earnings expectations. Amgen appoints David Gibbs
• Negative Sentiment: The FDA issued Amgen a warning letter over a promotional video for its Vectibix cancer drug, creating regulatory and compliance risk and potentially requiring corrective advertising. FDA warns Amgen over Vectibix promotional video
• Negative Sentiment: Some analysts caution that commercial uncertainties surrounding Imdelltra warrant a $328 price target and Underperform rating. Separately, Zacks said Amgen lacks key indicators supporting a likely earnings beat in next week’s report, increasing event risk ahead of results. Amgen analyst caution on Imdelltra

Analyst Upgrades and Downgrades

Several equities analysts have commented on the company. Weiss Ratings raised Amgen from a “buy (b)” rating to a “buy (b+)” rating in a research report on Thursday, October 8th. Cantor Fitzgerald lifted their target price on Amgen from $400.00 to $440.00 and gave the stock a “neutral” rating in a research report on Monday, October 5th. Royal Bank Of Canada lifted their target price on Amgen from $400.00 to $430.00 and gave the stock an “outperform” rating in a research report on Thursday, October 8th. BMO Capital Markets lowered their target price on shares of Amgen from $450.00 to $415.00 and set a “market perform” rating for the company in a research note on Monday, October 12th. Finally, Morgan Stanley cut their price target on shares of Amgen from $362.00 to $359.00 and set an “equal weight” rating on the stock in a report on Wednesday, October 7th. One research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, sixteen have issued a Hold rating and three have given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $389.71.

Amgen Profile

Amgen Inc is a biotechnology company that discovers, develops, manufactures and delivers medicines for serious illnesses. Its research focuses on areas including oncology, cardiovascular disease, inflammation, bone health, nephrology and neuroscience.

The company’s products include biologic and specialty medicines such as Enbrel for inflammatory diseases, Prolia and Evenity for osteoporosis, Xgeva for skeletal-related complications, Repatha for cardiovascular risk reduction, Otezla for inflammatory conditions, Tezspire for severe asthma, Blincyto for certain blood cancers, and Lumakras for specific cancers.

Founded in 1980, Amgen is headquartered in Thousand Oaks, California.